A new and strong scientific commitment to the medicinal use of preparations of the Cannabis sativa plant, cannabinoids, brought facts, evidences and proofs of their importance to health and it was a tragedy for humanity to be included in the 1961 United Nations Convention on narcotics as a drug without medical use. We owe patients who suffered from chronic pain, cancer, depression, insomnia, neurological and convulsive disorders, this new way of having and being able to use these products.


In 1990 it was discovered that there are Cannabis receptors into the brain and into the body, like a true endocannabinoic system related to the control of important biological functions, such as cognition, memory, pain, sleep and immune function, but the research was incipient because of that mistaken classification.

In the 1990s, people from around the world, especially from the United States, petitioned for a review of that classification, resulting in the approval of referendums, which legalized the medical use of Cannabis for people with the variety of diseases announced above.

In 1999, Canada, as a result of court decisions requesting authorization for use, introduced a medical cannabis program that continues today.

In 2001, Israel, in 2003, the Netherlands, in 2011, Switzerland, in 2013, the Czech Republic, in 2016, Australia, in 2017, Germany, legislated to allow the medical use of Cannabis and subsequent clinical trials provided the basis for granting marketing authorization in many Member States of the European Union.

Having authorization means that an order has been submitted to the regulatory authorities that granted it and this implies the verification of planting, harvesting, material analysis and subsequently that the product will undergo several clinical tests and that the safety, effectiveness and side effects have been examined by the Ministries competent, for the final to be marketed.


Cannabis contains hundreds of chemicals. More than 100 of them are known as cannabinoids. They are in the trichomes, light and tiny hair that protrude from the flowers and leaves of the plants. These cannabinoids have effects on cell receptors into the brain and body and can change the way these cells behave and communicate with each other.


The most researched cannabinoid is THC (tetrahydrocannabinol). It is responsible for how your brain and body respond to cannabis. The potency (concentration or strength) of THC is often shown as a percentage of THC by weight or volume of an oil, which is an average of 15% and can reach 30%. And in these percentages it has the psychoactive principle and causes psychotropic effect, the corresponding “cheap”. Cannabis that contains very low amounts of THC in flowers and leaves (less than 0.3%) is classified as hemp.


Another cannabinoid is CBD (cannabidiol) which has no psychotropic effect and has numerous therapeutic effects. It must be used under medical supervision. It is called medicinal cannabis. Randomized clinical trials report that Cannabis is useful in the treatment of pain, spasms, nausea, anorexia and seizures, neuropathic pain, among others and has had no serious adverse effects. The greatest scientific evidence is its effectiveness in the treatment of the most cruel childhood epilepsy syndromes such as Dravet's and Lennox-Gastaut's that do not respond to other medications. In several studies, CBD reduced seizures and in some cases stopped them altogether.


Medical cannabis is administered by spraying (infusions), smoking or in edible preparations, concentrates, capsules and topicals. It is sold as a supplement and not as a medicine and the main purpose of its use is to relieve symptoms, cure and improve function and quality of life in general.


The size of the global pharmaceutical industry market was valued at $ 1.7 trillion in 2019 according to the Statista report and is expected to grow at a compound annual growth rate (CAGR) of 5% to 8% from 2020 to 2024; AstraZeneca in 2020, invested US $ 133 million to expand his factory in Australia and PCI Pharma Services expanded Tredegar in the United Kingdom for high top medicine. Intelligent, integrated and data-rich operations result in the production of these drugs with greater precision and reduced costs, attracting more consumers due to ease of use, product safety and precise dosing, in short the quality they demand.

The size of the global medical marijuana Market, driven by growing research and development as well as financial support from governments and companies, according to GrandViewResearch is expected to reach $ 73.6 billion by 2027, expanding to an 18.1% CAGR of 2018 to 2027.

The increasing legalization of Cannabis for medical and adult use will promote its growth. The chronic pain segment led the market in 2019. The application for mental disorders, anxiety, depression and Alzheimer's is growing.

North America liberated the sector with 88.4% in 2019 due to the expansion of legalizations and the liberalism of regulations. Legalization in Canada, Australia, Poland, Germany and Israel should also promote the growth of this market and create lucrative opportunities for its investors.